Trial · NCT07359404
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
NCT07359404, Phase 2, Enrolling by invitation, YING FAN
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC. Trials, record NCT07359404. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07359404
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
- NCT number
- NCT07359404
- Status
- Enrolling by invitation
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- YING FAN
- Conditions
- Advanced Breast Cancer
- Interventions
- Sacituzumab Govitecan (SG), Bevacizumab
- First posted
- 2026-01-22
- Last updated
- 2026-01-22
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival | From start of treatment until disease progression or death, assessed up to approximately 32 months (based on study completion date of Dec 2026) | |
| Primary | Incidence and Severity of Adverse Events (Safety) | From start of treatment through 90 days after the last dose of study drug. | |
| Secondary | Objective Response Rate | From start of treatment until disease progression or intolerance, assessed every 2 cycles, assessed up to approximately 32 months | |
| Secondary | Overall Survival | From start of treatment until death, assessed up to approximately 32 months | |
| Secondary | Disease Control Rate | From start of treatment until disease progression or intolerance, assessed up to approximately 32 months | |
| Secondary | Duration of Response | From date of first response until disease progression or death,assessed up to approximately 32 months | |
| Secondary | 6-month Progression-Free Survival Rate | At 6 months after treatment initiation | |
| Secondary | 6-month Overall Survival Rate | At 6 months after treatment initiation | |
| Other | Trop-2 Expression Level | From baseline up to approximately 32 months | Assessment of Trop-2 expression in tumor tissue using Immunohistochemistry (IHC). Results are reported as Histochemical Score (H-score, ranging from 0 to 300). This measure will be analyzed to explore the association with efficacy outcomes (PFS, ORR). |
| Other | UGT1A1 Genotype Status | From baseline up to approximately 32 months | Assessment of UGT1A1 gene polymorphisms (e.g., 1, 28 alleles) in blood or tissue samples using PCR or sequencing. Results are categorized by genotype (e.g., homozygous wild-type, heterozygous, homozygous mutant). This measure will be analyzed to explore the association with safety outcomes (adverse events). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07359404
GET https://conductscience.org/api/trials/v1/NCT07359404/registered